Definium Therapeutics: Funding, Investors & Team (Sep 2026)
Definium Therapeutics provides psychedelic-inspired medicines and therapies for substance abuse disorders and other mental illnesses. The company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances including Psilocybin, LSD, MDMA, DMT, and an Ibogaine derivative, 18-MC.
Definium Therapeutics has raised $805M across 1 funding round on record, the most recent an undisclosed round of $805M announced in Jun 2026.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Definium Therapeutics Company Profile and Key Stats
Latest funding round on record: Jun 2026.
Definium Therapeutics Funding Rounds
Definium Therapeutics Founders and Leadership Team
No contact details are on record for this team yet.
Definium Therapeutics Funding Compared to Other Biotechnology Startups
Definium Therapeutics' latest round of $805M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Definium Therapeutics in Biotechnology and New York
Companies Similar to Definium Therapeutics
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
Definium Therapeutics Funding FAQs
What does Definium Therapeutics do?
Definium Therapeutics provides psychedelic-inspired medicines and therapies for substance abuse disorders and other mental illnesses. The company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances including Psilocybin, LSD, MDMA, DMT, and an Ibogaine derivative, 18-MC.
How much funding has Definium Therapeutics raised?
Definium Therapeutics has raised $805M across 1 round on record. The most recent is an undisclosed round of $805M announced in Jun 2026.
When did Definium Therapeutics last raise funding?
Definium Therapeutics' most recent funding round on record is an undisclosed round of $805M, announced in Jun 2026.
Who founded Definium Therapeutics?
FundedIQ lists Robert Barrow (Founder) at Definium Therapeutics.
Where is Definium Therapeutics headquartered?
Definium Therapeutics is based in New York, New York, United States.
How many employees does Definium Therapeutics have?
Definium Therapeutics is in the 101-250 employee band.
How does Definium Therapeutics' funding compare to other Biotechnology startups?
Definium Therapeutics' latest round of $805M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Definium Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Definium Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.